Hovione Virtual Run

The biggest race in Loures - Portugal is back and it's virtual!

The Hovione Run is back, in virtual format! The biggest race in Loures/ Portugal, this year goes global and will have national and international participants.

Between the 4th, 5th and 6th of June, athletes will be able to travel one of the three distances available:

Registration is completely free.

REGISTER HERE

AWARDS

Virtual finisher medal
Diploma to be consulted in the results menu of the website www.xistarca.pt *
Virtual cup for the top 3 male and female runners from each distance

* At the end of the race, you must answer a questionnaire, which will be sent to all registered participants and which will also be available on this page, indicating the race time and a photo that proves the same.

CLASSIFICATIONS

The general classification will be published on the event’s website, taking as correct the information that will be sent to the organization, not being approved for competitive purposes.

Learn more at www.xistarca.pt

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com

Press Clipping

Contract Pharma, 7 May 2026